Fig. 7

TCDCA inhibited the growth of GBM in vivo. A Experimental Scheme for orthotopic GBM mice model. B The body weight of the tumor-bearing mice was monitored every day (n = 6 mice, per group). C Bioluminescent imaging of disseminated GL261-Luc orthotopic xenograft mice at different time points posttreatment with TCDCA and the control. D Fold change in average radiance mouse at experimental endpoint was analyzed for each treatment group (n = 6/group, t-test). E Representative images of HE staining of whole-brain sections from TCDCA and control-treated group. Scale bar, 1 mm. F Quantification analysis of the area of GBM in (E) (normalized to control, n = 4/group, t-test). G Representative images of Ki67 staining of whole-brain sections from TCDCA and control-treated group. Scale bar, 20 μm. H Quantification analysis of the area of GBM in (G) (normalized to control, n = 9/group, t-test) I Western blot detected the expression of HMGCS1, HMGCR and GPX4 in orthotopic tumor tissue. J–L Quantification of the relative level of HMGCS1 (J), HMGCR (K) and GPX4 (L) as shown in (G) (normalized to control, n = 4/per group, t-test). Data were mean + SEM. ^****P < 0.0001, ^*P < 0.05